ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1601

Interleukin-6 Disrupts Blood-cerebrospinal Fluid Barrier Permeability in Murine Neuropsychiatric Lupus
Abstract Number: 2446

Intermittent Fasting Attenuates Cognitive Dysfunction in Murine Systemic Lupus Erythematosus
Abstract Number: 0815

Intermittent Fasting Reduces Crystal-induced Inflammation
Abstract Number: 1130

Interobserver Reliability and Sensitivity to Change of a Composite Ocular Inflammatory Activity Index: UVEDAI
Abstract Number: 2212

Interpretation of Disease-specific Questionnaires on Disease Activity, Functional Capacity and Quality of Life in Daily Practice in Axial Spondyloarthritis
Abstract Number: 0628

Interstitial Lung Disease in Very Early Systemic Sclerosis
Abstract Number: 1374

Interstitial Lung Disease Is Frequent in Primary Sjögren’s Syndrome and Is Associated with Reduced Survival
Abstract Number: 1618

Intervention to Improve Medication Adherence Among Patients with SLE
Abstract Number: 2035

Intimate Partner Violence Is Associated with a Poorer Health-Related Quality of Life (HR-QoL) in Women with Systemic Lupus Erythematous
Abstract Number: 2042

Intraocular Cytokine Profiling of Autoimmune Uveitis
Abstract Number: 1914

Intravenous Immunoglobulins in the Treatment of Idiopathic Inflammatory Myopathies in a Region of Northern Spain: Analysis by Subtypes
Abstract Number: 1528

Intravenous or Subcutaneous Immunoglobulins as Potential Treatment for Gastrointestinal, Cutaneous and Vascular Involvement in Systemic Sclerosis: Data from an Italian Cohort of 65 Patients
Abstract Number: 1502

Introduction of Belimumab Within Five Years of the Onset of Systemic Lupus Erythematosus (SLE) Contributes to the Better Therapeutic Response; A Multi-center Retrospective Cohort Study
Abstract Number: 0875

INV-1498, a Promising Caspase Inhibitor, Exhibits Dose-dependent Therapeutic Efficacy in a Canine Model of Osteoarthritis
Abstract Number: 1966

Investigating Esophageal Involvement in Anti-Synthetase Syndrome: How to Discover the Submerged?

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].